vs

Side-by-side financial comparison of Northfield Bancorp, Inc. (NFBK) and Zymeworks Inc. (ZYME). Click either name above to swap in a different company.

Northfield Bancorp, Inc. is the larger business by last-quarter revenue ($41.3M vs $27.6M, roughly 1.5× Zymeworks Inc.). Zymeworks Inc. runs the higher net margin — -71.0% vs -1545.5%, a 1474.5% gap on every dollar of revenue. On growth, Zymeworks Inc. posted the faster year-over-year revenue change (72.6% vs 12.7%). Northfield Bancorp, Inc. produced more free cash flow last quarter ($52.5M vs $-31.8M).

Northfield Bancorp, Inc. is a regional bank holding company based in the United States, operating primarily across the U.S. Northeast region. It provides a full range of personal and commercial banking services including deposit accounts, mortgage loans, commercial lending, and wealth management solutions for retail consumers, small to medium-sized businesses and local community clients.

Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital th...

NFBK vs ZYME — Head-to-Head

Bigger by revenue
NFBK
NFBK
1.5× larger
NFBK
$41.3M
$27.6M
ZYME
Growing faster (revenue YoY)
ZYME
ZYME
+59.9% gap
ZYME
72.6%
12.7%
NFBK
Higher net margin
ZYME
ZYME
1474.5% more per $
ZYME
-71.0%
-1545.5%
NFBK
More free cash flow
NFBK
NFBK
$84.4M more FCF
NFBK
$52.5M
$-31.8M
ZYME

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
NFBK
NFBK
ZYME
ZYME
Revenue
$41.3M
$27.6M
Net Profit
$-27.4M
$-19.6M
Gross Margin
Operating Margin
-1263.3%
-80.1%
Net Margin
-1545.5%
-71.0%
Revenue YoY
12.7%
72.6%
Net Profit YoY
-343.6%
34.3%
EPS (diluted)
$-0.68
$-0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NFBK
NFBK
ZYME
ZYME
Q4 25
$41.3M
Q3 25
$39.2M
$27.6M
Q2 25
$38.9M
$48.7M
Q1 25
$34.8M
$27.1M
Q4 24
$36.7M
$31.0M
Q3 24
$31.8M
$16.0M
Q2 24
$31.5M
$19.2M
Q1 24
$31.3M
$10.0M
Net Profit
NFBK
NFBK
ZYME
ZYME
Q4 25
$-27.4M
Q3 25
$10.8M
$-19.6M
Q2 25
$9.6M
$2.3M
Q1 25
$7.9M
$-22.6M
Q4 24
$11.3M
$-23.5M
Q3 24
$6.5M
$-29.9M
Q2 24
$6.0M
$-37.7M
Q1 24
$6.2M
$-31.7M
Operating Margin
NFBK
NFBK
ZYME
ZYME
Q4 25
-1263.3%
Q3 25
37.7%
-80.1%
Q2 25
35.6%
-1.4%
Q1 25
31.0%
-94.5%
Q4 24
38.0%
-71.6%
Q3 24
27.9%
-213.8%
Q2 24
29.1%
-222.9%
Q1 24
27.2%
-376.9%
Net Margin
NFBK
NFBK
ZYME
ZYME
Q4 25
-1545.5%
Q3 25
27.4%
-71.0%
Q2 25
24.6%
4.8%
Q1 25
22.6%
-83.5%
Q4 24
30.7%
-75.8%
Q3 24
20.5%
-186.6%
Q2 24
18.9%
-195.8%
Q1 24
19.9%
-315.6%
EPS (diluted)
NFBK
NFBK
ZYME
ZYME
Q4 25
$-0.68
Q3 25
$0.27
$-0.26
Q2 25
$0.24
$0.03
Q1 25
$0.19
$-0.30
Q4 24
$0.27
$-0.32
Q3 24
$0.16
$-0.39
Q2 24
$0.14
$-0.49
Q1 24
$0.15
$-0.42

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NFBK
NFBK
ZYME
ZYME
Cash + ST InvestmentsLiquidity on hand
$164.0M
$64.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$690.1M
$320.1M
Total Assets
$5.8B
$397.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NFBK
NFBK
ZYME
ZYME
Q4 25
$164.0M
Q3 25
$131.7M
$64.8M
Q2 25
$97.6M
$98.3M
Q1 25
$101.7M
$76.2M
Q4 24
$167.7M
$66.1M
Q3 24
$232.9M
$122.4M
Q2 24
$153.5M
$71.0M
Q1 24
$238.8M
$114.8M
Total Debt
NFBK
NFBK
ZYME
ZYME
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$666.4M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
NFBK
NFBK
ZYME
ZYME
Q4 25
$690.1M
Q3 25
$719.6M
$320.1M
Q2 25
$710.3M
$334.5M
Q1 25
$711.1M
$325.0M
Q4 24
$704.7M
$338.8M
Q3 24
$699.6M
$367.0M
Q2 24
$693.0M
$406.2M
Q1 24
$698.4M
$438.0M
Total Assets
NFBK
NFBK
ZYME
ZYME
Q4 25
$5.8B
Q3 25
$5.7B
$397.3M
Q2 25
$5.7B
$408.4M
Q1 25
$5.7B
$425.5M
Q4 24
$5.7B
$463.1M
Q3 24
$5.7B
$487.2M
Q2 24
$5.7B
$515.6M
Q1 24
$5.9B
$553.8M
Debt / Equity
NFBK
NFBK
ZYME
ZYME
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.95×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NFBK
NFBK
ZYME
ZYME
Operating Cash FlowLast quarter
$53.7M
$-31.4M
Free Cash FlowOCF − Capex
$52.5M
$-31.8M
FCF MarginFCF / Revenue
127.1%
-115.2%
Capex IntensityCapex / Revenue
2.8%
1.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$89.2M
$-65.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NFBK
NFBK
ZYME
ZYME
Q4 25
$53.7M
Q3 25
$13.9M
$-31.4M
Q2 25
$14.1M
$12.1M
Q1 25
$9.4M
$-3.4M
Q4 24
$31.1M
$-41.5M
Q3 24
$14.0M
$-5.9M
Q2 24
$6.9M
$-25.0M
Q1 24
$4.2M
$-37.7M
Free Cash Flow
NFBK
NFBK
ZYME
ZYME
Q4 25
$52.5M
Q3 25
$13.6M
$-31.8M
Q2 25
$13.9M
$11.6M
Q1 25
$9.2M
$-3.4M
Q4 24
$30.0M
$-41.8M
Q3 24
$13.7M
$-6.8M
Q2 24
$6.7M
$-25.6M
Q1 24
$3.8M
$-37.9M
FCF Margin
NFBK
NFBK
ZYME
ZYME
Q4 25
127.1%
Q3 25
34.6%
-115.2%
Q2 25
35.7%
23.7%
Q1 25
26.3%
-12.6%
Q4 24
81.6%
-134.8%
Q3 24
43.2%
-42.4%
Q2 24
21.1%
-133.0%
Q1 24
12.1%
-377.5%
Capex Intensity
NFBK
NFBK
ZYME
ZYME
Q4 25
2.8%
Q3 25
0.8%
1.5%
Q2 25
0.6%
1.1%
Q1 25
0.7%
0.1%
Q4 24
3.1%
1.0%
Q3 24
0.7%
5.6%
Q2 24
0.8%
3.1%
Q1 24
1.4%
1.8%
Cash Conversion
NFBK
NFBK
ZYME
ZYME
Q4 25
Q3 25
1.29×
Q2 25
1.48×
5.21×
Q1 25
1.20×
Q4 24
2.76×
Q3 24
2.14×
Q2 24
1.16×
Q1 24
0.68×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons